Uses of Atibeza

Atibeza medicine 200 mg is a product indicated for patients with high triglycerides and blood lipids to reduce the index and improve pathological symptoms caused by hypertriglyceridemia. To better understand what Agibeza 200 is, what are the uses of Agibeza, let's learn more in the article below.

Atibeza has the main ingredient Bezafibrate which belongs to the group of drugs used to treat cardiovascular diseases. The drug is prepared in the form of 200mg film-coated tablets.
Atibeza medicine 200mg is prescribed by doctors to use in the following cases:
Treatment of primary hyperlipoproteinemia. Treatment of secondary hyperlipoproteinemia: hypercholesterolemia after dieting or lifestyle changes but no improvement Treatment of severe secondary hypertriglyceridemia for a long time despite the underlying disease being treated (eg, diabetes mellitus) Street )

2.1 Mechanism of Action Atibeza 200 mg Bezafibrate reduces high blood lipids (triglycerides and cholesterol). Increases in VLDL and LDL were reduced by treatment with bezafibrate, while HDL levels were increased. The activity of triglyceride lipases (liver lipoprotein lipase and lipoprotein lipase) involved in the catabolism of triglyceride-rich lipoproteins is increased by bezafibrate. During enhanced breakdown of triglyceride-rich lipoproteins (chylomicrons, VLDL), precursors for the formation of HDL are formed, which explains the increase in HDL. Furthermore, cholesterol biosynthesis is reduced by bezafibrat, which is accompanied by stimulation of LDL receptor-mediated lipoprotein catabolism.
Studies have shown that bezafibrate is effective in the treatment of hyperlipidemia in patients with diabetes mellitus. Some cases have been shown to be beneficial in reducing fasting blood sugar. There is evidence that treatment with fibrates can reduce coronary heart disease events, but they have not been shown to reduce all-cause mortality in primary or secondary CVD prevention.
2.2 Contraindications of Atibeza 200 mg Hypersensitivity to bezafibrate or any component of Atibeza or other fibrates. Patients with severe liver disease (except fatty liver infiltrates associated with elevated triglyceride values). Patients with gallbladder disease with or without gallstones. Patients with severe renal impairment or nephrotic syndrome (serum creatinine > 135 micromol/l or creatinine clearance <60 mL/min.) and those on dialysis. Patient is taking HMG CoA reductase inhibitors (statins) Known phototoxic or photoallergic reactions to fibrates. 2.3 Precautions for use of Atibeza 200 mg There are limited data on the use of bezafibrate in pregnant women. Animal studies are not sufficient to determine reproductive toxicity. Atibeza 200mg is not recommended during pregnancy and women of childbearing potential not using contraception.
Not enough is known about the excretion of bezafibrate or its metabolites in human milk. Therefore, a possible risk to the nursing infant cannot be excluded. A decision to discontinue breast-feeding or to discontinue/abstain treatment with Atibeza 200mg must be made taking into account the benefit of breastfeeding and the benefit of treatment to the mother.
2.4 Side effects of the drug Atibeza Lymphatic and blood system disorders: Very rare Thrombocytopenia, thrombocytopenic purpura. Immune system disorders: Uncommon hypersensitivity reactions including anaphylaxis. Nutritional and metabolic disorders: Usually decreased appetite. Nervous system disorders: Uncommon dizziness, headache Psychiatric disorders : Rarely depression, insomnia. Digestive disorders ... It is best in the course of taking the drug, if there are any unusual problems, the patient should consult a doctor for appropriate indications.
2.5 Drug Interactions Atibeza 200mg should be used with caution in patients taking coumarin-type anticoagulants, the effects of which may be increased. The dose of anticoagulants should be reduced to 50% and adjusted again by monitoring coagulation.
As bezafibrate improves glucose utilization, the effects of antidiabetic drugs, including insulin, may be enhanced. Hypoglycaemia has not been reported although it may warrant enhanced monitoring of blood glucose status for a short time after administration of Atibeza 200mg
In isolated cases, a marked decrease although possible Reversal of renal function (with a corresponding increase in serum creatinine) has been reported in transplant patients treated with immunosuppressants and concomitantly with Atibeza. Therefore, renal function should be closely monitored in these patients and in the event of relevant significant changes in laboratory parameters, bezafibrate should be discontinued if necessary.
MAO inhibitors (potentially hepatotoxic) should not be taken with Atibeza 200 mg. Interactions between HMG CoA reductase inhibitors and fibrates can vary in nature and intensity depending on the combination of drugs used. Pharmacodynamic interactions between these two classes of drugs may, in some cases, also contribute to an increased risk of myopathy for statin-specific dosing recommendations that also refer to the SPC of the product concerned.

Swallow the tablet whole with cooled boiled water, do not crush the tablet or mix it with other mixtures. Take medicine after meals. Recommended dosage: 2 times a day, 1 tablet each time. Should be taken in the morning and evening.
No specific effects of acute overdose are known (other than rhabdomyolysis). There is no specific antidote. Therefore, appropriate symptomatic therapy is recommended in case of overdose. In case of rhabdomyolysis, bezafibrate should be discontinued immediately and renal function carefully monitored.
Knowing the information about the drug Atibeza is one of the important steps for the most effective use of the drug. Therefore, before using, you should read the instructions carefully or discuss more with your doctor or pharmacist.